Search Details

Word: waxman (lookup in dictionary) (lookup stats)
Dates: during 1980-1989
Sort By: most recent first (reverse)


Usage:

...Paul Waxman, in charge of Steve's publicity, explained that advertising is "simple and non pretentious. Students were our first fans and our loyalty has always started in the colleges...

Author: By Helen Lee, | Title: Steve's Big At Colleges Across East | 4/27/1983 | See Source »

...just want to get people acquainted with our solid, wholesome product," Waxman said, adding, "then we'll leave it up to our customers to know it's the best...

Author: By Helen Lee, | Title: Steve's Big At Colleges Across East | 4/27/1983 | See Source »

...found that only 58 were on the market or even under investigation by drug manufacturers. Furthermore, more than two-thirds of the orphan products that have been approved by the FDA over the past decade were developed with the help of Government or university funding. Says Subcommittee Chairman Henry Waxman: "That's an unhappy commentary on industry effort...

Author: /time Magazine | Title: Medicine: Adopting Orphan Drugs | 10/11/1982 | See Source »

...redress the problem, California Democrat Waxman last year proposed legislation that would provide financial incentives to companies undertaking or phan-drug research. Last week such bills were overwhelmingly approved by the House and the Senate. Under the provisions of the House bill, drug companies were to receive a 90% tax credit for expenses incurred in orphan-drug development, but the Senate struck this credit and substituted an appropriation of $9 million. The House measure also called for a seven-year period of exclusive marketing rights for unpatentable orphan products. It provided that in the absence of any alternative treatment, orphan...

Author: /time Magazine | Title: Medicine: Adopting Orphan Drugs | 10/11/1982 | See Source »

...everyone is pleased with the legislation. In fact, the Administration issued a position paper last week opposing the measure. The statutory creation of an interagency orphan-products board, the Administration said, was superfluous be cause an equivalent panel existed within HHS. Waxman had already altered the bill to accommodate earlier Administration objections. Both the FDA and the Pharmaceutical Manufacturers Association had opposed a provision in the original bill that would have permitted approval of orphan drugs after one successful human clinical trial. With that provision dropped and other changes made, the P.M.A. now supports the bill, though it continues...

Author: /time Magazine | Title: Medicine: Adopting Orphan Drugs | 10/11/1982 | See Source »

Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | Next